Procter & Gamble Health Ltd Stock Price Today (NSE: PGHL)
Fundamental Score
Procter & Gamble Health Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Procter & Gamble Health Ltd share price today is ₹6030.50, down 0.54% on NSE/BSE as of 19 June 2026. Procter & Gamble Health Ltd (PGHL) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹9.65K (Cr). The 52-week high for PGHL share price is ₹6739.00 and the 52-week low is ₹4707.00. At a P/E ratio of 31.44x, PGHL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 36.42% and a debt-to-equity ratio of 0.01.
Procter & Gamble Health Ltd Share Price Chart — NSE/BSE Historical Performance
Procter & Gamble Health Ltd share price chart: 20.71% return over the past month. 52-week high ₹6739.00, 52-week low ₹4707.00.
Procter & Gamble Health Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹5921.50 | ₹6099.50 | ₹5921.50 | ₹6030.50 | 14.72K (Cr) | |
| ₹6056.00 | ₹6169.50 | ₹5984.00 | ₹6063.00 | 48.35K (Cr) | |
| ₹6076.00 | ₹6389.00 | ₹5953.00 | ₹6056.00 | 68.81K (Cr) | |
| ₹5949.00 | ₹6700.00 | ₹5848.50 | ₹6247.50 | 4.86L (Cr) | |
| ₹5749.00 | ₹5760.00 | ₹5599.00 | ₹5652.50 | 15.62K (Cr) | |
| ₹5649.00 | ₹5741.00 | ₹5560.50 | ₹5726.00 | 19.38K (Cr) | |
| ₹5455.00 | ₹5685.00 | ₹5435.00 | ₹5553.00 | 63.85K (Cr) | |
| ₹5365.00 | ₹5475.00 | ₹5318.50 | ₹5455.00 | 25.05K (Cr) | |
| ₹5306.00 | ₹5399.00 | ₹5306.00 | ₹5358.00 | 8.11K (Cr) | |
| ₹5220.00 | ₹5365.00 | ₹5220.00 | ₹5340.50 | 10.06K (Cr) |
Procter & Gamble Health Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹6056.00 | ₹6169.50 | ₹5921.50 | ₹6030.50 | -0.42% | |
| ₹5235.50 | ₹6700.00 | ₹5067.00 | ₹6056.00 | +15.67% | |
| ₹4829.00 | ₹5260.00 | ₹4707.00 | ₹5216.90 | +8.03% | |
| ₹4949.00 | ₹5011.00 | ₹4725.00 | ₹4798.80 | -3.03% | |
| ₹5300.50 | ₹5480.00 | ₹4862.00 | ₹4900.50 | -7.55% | |
| ₹5679.00 | ₹5912.00 | ₹5290.00 | ₹5303.00 | -6.62% | |
| ₹5723.00 | ₹5870.00 | ₹5541.50 | ₹5703.00 | -0.35% | |
| ₹6174.00 | ₹6180.00 | ₹5698.50 | ₹5722.50 | -7.31% | |
| ₹6306.50 | ₹6409.00 | ₹6000.00 | ₹6166.50 | -2.22% | |
| ₹6340.00 | ₹6594.00 | ₹6208.00 | ₹6307.50 | -0.51% | |
| ₹5895.50 | ₹6739.00 | ₹5895.50 | ₹6370.00 | +8.05% | |
| ₹5880.50 | ₹6100.00 | ₹5600.00 | ₹5895.50 | +0.26% |
AI Research Briefing
Powered by Gemini · 2026-04-10
PGHL is a bond proxy; collect the dividend, but don't expect growth.
WHAT'S HAPPENING NOW
Procter & Gamble Health (PGHL) has scheduled a board meeting on May 26, 2026, to approve FY26 financial results and consider a final dividend. In January 2026, parent company Procter & Gamble acquired Wonderbelly, a manufacturer of digestive health products. PGHL clarified on April 6, 2026, that it doesn't qualify as a 'Large Corporate' under SEBI regulations due to zero outstanding borrowings.
CORE STORY
PGHL is a play on India's growing consumer healthcare market, specifically over-the-counter products, vitamins, and supplements. The market prices it as a stable dividend-paying consumer healthcare company, not a high-growth pharma play.
- Consistent dividend payouts
- Zero debt
- Stable profitability
- Increase in dividend payout ratio
- Acquisition of new brands to boost sales
- Significant growth in the Indian consumer healthcare market
- Anemic sales growth
- Reliance on a few key brands
- Fair valuation limits upside
- Mid-cap: liquidity risk
FII increased stake by 0.25%, DII decreased stake by 0.25%.
Indian pharma sector projected to reach $130 billion by 2030, but faces export headwinds.
Yes, Free Cash Flow 5Y: ₹906.56 Cr
Stable dividend income with limited growth potential. Monitor for changes in dividend policy and sales performance.
Primary Thesis Risk
Dividend cut will trigger a sell-off.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Procter & Gamble Health Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Procter & Gamble Health Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PGHL across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (36.42%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (47.75%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (26.17%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (785.71x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹906.56 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Growth History (0.16% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Procter & Gamble Health Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Procter & Gamble Health Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
50/100 | ₹6030.50₹6031 | ₹9645.74₹9645.74 | 31.44Average 31.4 Average | 36.42%Excellent 36.42% Excellent | 47.75%Excellent 47.75% Excellent | 0.01Excellent 0.0 Excellent | 8.11%Good 8.11% Good | 0.16%Average 0.16% Average | 2.15% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Procter & Gamble Health Ltd PE Ratio History
Historical price-to-earnings ratio for PGHL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹121.00 | ₹5238.05 | 43.3x |
| FY 2023 | ₹138.00 | ₹4947.75 | 35.9x |
| FY 2022 | ₹115.98 | ₹3953.00 | 34.1x |
| FY 2021 | ₹107.00 | ₹5338.40 | 49.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Procter & Gamble Health Ltd Dividend History
Annual cash dividends paid by PGHL — dividend yield 2.15%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹414.99 Cr |
| FY 2023 | ₹93.79 Cr |
| FY 2022 | ₹283.85 Cr |
| FY 2021 | ₹381.78 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Procter & Gamble Health Ltd Quarterly Performance
Latest quarterly metrics for PGHL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
3.67%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
7.54%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
0.16%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
8.11%
Compounded annual net profit growth over 5 years
Procter & Gamble Health Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PGHL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Procter & Gamble Health Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Procter & Gamble Health Ltd (PGHL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Procter & Gamble Health Ltd
About PGHL (Procter & Gamble Health Ltd)
Procter & Gamble Health Ltd is a dynamic player in the pharmaceutical sector, deeply rooted in both the Indian and global markets. The company is dedicated to enhancing consumer we...ll-being through a diverse portfolio of over-the-counter medicines and a comprehensive range of vitamins, minerals, and supplements. PGHL's commitment to quality and innovation is evident in its focus on providing accessible healthcare solutions, aimed at improving the everyday lives of individuals and families. With a strong emphasis on research and development, PGHL continuously strives to formulate effective and reliable products that address a variety of health needs, strengthening its position as a trusted name in the consumer healthcare landscape. The company's recognized and established brand portfolio, which includes names like Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas, reflects its longstanding presence and trusted reputation among consumers. These brands encompass a wide spectrum of health solutions, targeting various needs from multivitamin supplementation to specialized treatments. Procter & Gamble Health Ltd leverages these established brands to reach diverse consumer segments, reinforcing its commitment to providing accessible healthcare solutions. This strategic approach allows the company to maintain a competitive edge and to foster lasting relationships with customers who depend on the quality and reliability of PGHL products. Originally established as Merck Limited in 1967, the company underwent a transformative rebranding to Procter & Gamble Health Limited in May 2019, marking a significant milestone in its journey. This transition not only reflects the company's integration into the global Procter & Gamble network but also signifies its renewed focus on consumer healthcare. Procter & Gamble Health Ltd continues to build upon its legacy of scientific expertise and market understanding, while leveraging the resources and global reach of its parent company. With a history of delivering innovative healthcare solutions, PGHL is poised to continue its mission of improving health and well-being for consumers across India and beyond.
Company Details
Key Leadership
Corporate Events
PGHL Share Price: Frequently Asked Questions
What is the current share price of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd (PGHL) trades at ₹6030.50 on NSE and BSE. Market cap ₹9.65K (Cr). Educational data only.
What is the P/E ratio of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd has a P/E of 31.44x vs industry average 31.77x.
What is the Bull Run score for Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd has a Bull Run score of 50/100 based on 25+ financial parameters.
Does Procter & Gamble Health Ltd pay dividends?
Procter & Gamble Health Ltd has a dividend yield of 2.15%. Past dividends don't guarantee future payments.
What is the ROE of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd has ROE of 36.42%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd has debt-to-equity of 0.01.
Is Procter & Gamble Health Ltd a good investment?
Bull Run gives Procter & Gamble Health Ltd a score of 50/100. This is not investment advice — consult a SEBI-registered advisor.